

Susanna V Ulahannan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5857723/publications.pdf>

Version: 2024-02-01

25
papers

1,241
citations

933447

10
h-index

996975

15
g-index

26
all docs

26
docs citations

26
times ranked

2229
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | A Phase 1a/b Open-Label, Dose-Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 882-892. | 7.0 | 29 |
| 2 | Preclinical Evaluation and Phase Ib Study of Prexasertib, a CHK1 Inhibitor, and Samotolisib (LY3023414), a Dual PI3K/mTOR Inhibitor. <i>Clinical Cancer Research</i> , 2021, 27, 1864-1874. | 7.0 | 20 |
| 3 | Reversible HER2 antibody-drug conjugate-induced ocular toxicity. <i>Canadian Journal of Ophthalmology</i> , 2021, , . | 0.7 | 7 |
| 4 | A Phase 1b Trial of Prexasertib in Combination with Standard-of-Care Agents in Advanced or Metastatic Cancer. <i>Targeted Oncology</i> , 2021, 16, 569-589. | 3.6 | 10 |
| 5 | A Phase 1, Open-Label Study of MGD013, a Bispecific DART [®] Molecule Binding PD-1 and LAG-3 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2020, 136, 21-22. | 1.4 | 13 |
| 6 | VEGF. , 2017, , 537-543. | | 0 |
| 7 | Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2017, 66, 545-551. | 3.7 | 624 |
| 8 | Population attributable fractions of risk factors for hepatocellular carcinoma in the United States. <i>Cancer</i> , 2016, 122, 1757-1765. | 4.1 | 245 |
| 9 | Pancreatic Squamous Cell Carcinoma. <i>Pancreas</i> , 2016, 45, 1432-1437. | 1.1 | 43 |
| 10 | Modulation of tumor eIF4E by antisense inhibition: A phase I/II translational clinical trial of ISIS 183750 [®] an antisense oligonucleotide against eIF4E [®] in combination with irinotecan in solid tumors and irinotecan [®] refractory colorectal cancer. <i>International Journal of Cancer</i> , 2016, 139, 1648-1657. | 5.1 | 55 |
| 11 | Hepatocellular carcinoma and immune therapy, from a clinical perspective; where are we?. <i>Hepatic Oncology</i> , 2016, 3, 183-185. | 4.2 | 2 |
| 12 | Pancreatic squamous cell carcinoma: Epidemiology, clinicopathologic characteristics, and outcomes.. <i>Journal of Clinical Oncology</i> , 2016, 34, 220-220. | 1.6 | 1 |
| 13 | Abstract 3421: Epidemiology and survival in patients with extragastric signet ring carcinoma. , 2016, , . | | 0 |
| 14 | Abstract 5015: Pretreatment carcinoembryonic antigen levels predict survival in patients with rectal adenocarcinoma. , 2016, , . | | 0 |
| 15 | A phase II study of TRC105 [®] in patients with hepatocellular carcinoma who have progressed on sorafenib. <i>United European Gastroenterology Journal</i> , 2015, 3, 453-461. | 3.8 | 36 |
| 16 | Identification of active chemotherapy regimens in advanced biliary tract carcinoma: a review of chemotherapy trials in the past two decades. <i>Hepatic Oncology</i> , 2015, 2, 39-50. | 4.2 | 10 |
| 17 | Phase I/II study of ISIS 183750 in combination with irinotecan for advanced solid tumors or colorectal cancer: Final results.. <i>Journal of Clinical Oncology</i> , 2015, 33, 639-639. | 1.6 | 2 |
| 18 | Curative treatments and survival benefit in elderly patients with hepatocellular carcinoma: A SEER population-based analysis.. <i>Journal of Clinical Oncology</i> , 2015, 33, 355-355. | 1.6 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | A phase I/II study of TRC105 in combination with sorafenib in hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2015, 33, 291-291. | 1.6 | 0 |
| 20 | Abstract 875: Risk factors for hepatocellular carcinoma (HCC) by race/ ethnicity in the United States. , 2015, , . | | 0 |
| 21 | Earlier presentation and application of curative treatments in hepatocellular carcinoma. Hepatology, 2014, 60, 1637-1644. | 7.3 | 78 |
| 22 | Paired tumor biopsy analysis and safety data from a pilot study evaluating Tremelimumab - a monoclonal antibody against CTLA-4 - in combination with ablative therapy in patients with hepatocellular carcinoma (HCC). , 2014, 2, . | | 0 |
| 23 | TRC105 for the treatment of hepatocellular carcinoma: Preclinical data and preliminary results from two clinical trials evaluating monotherapy and combination with sorafenib.. Journal of Clinical Oncology, 2014, 32, 211-211. | 1.6 | 0 |
| 24 | Disconnect between earlier presentation patterns and application of curative treatments in HCC.. Journal of Clinical Oncology, 2014, 32, 187-187. | 1.6 | 0 |
| 25 | Antiangiogenic Agents in Combination with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer. Cancer Investigation, 2011, 29, 325-337. | 1.3 | 66 |